TWI874345B - 包含經修飾il-2多肽之多肽及其用途 - Google Patents

包含經修飾il-2多肽之多肽及其用途 Download PDF

Info

Publication number
TWI874345B
TWI874345B TW109100336A TW109100336A TWI874345B TW I874345 B TWI874345 B TW I874345B TW 109100336 A TW109100336 A TW 109100336A TW 109100336 A TW109100336 A TW 109100336A TW I874345 B TWI874345 B TW I874345B
Authority
TW
Taiwan
Prior art keywords
polypeptide
antigen binding
binding domain
cancer
domain binds
Prior art date
Application number
TW109100336A
Other languages
English (en)
Chinese (zh)
Other versions
TW202043259A (zh
Inventor
約翰 C 湯門
伯瑞登 P 艾克曼
凱特琳 M 威爾斯
佛羅里安 薩梅爾
布萊恩 貝克倫
Original Assignee
美商因荷布瑞克斯生物科學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商因荷布瑞克斯生物科學公司 filed Critical 美商因荷布瑞克斯生物科學公司
Publication of TW202043259A publication Critical patent/TW202043259A/zh
Application granted granted Critical
Publication of TWI874345B publication Critical patent/TWI874345B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW109100336A 2019-01-07 2020-01-06 包含經修飾il-2多肽之多肽及其用途 TWI874345B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789075P 2019-01-07 2019-01-07
US62/789,075 2019-01-07

Publications (2)

Publication Number Publication Date
TW202043259A TW202043259A (zh) 2020-12-01
TWI874345B true TWI874345B (zh) 2025-03-01

Family

ID=69374426

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109100336A TWI874345B (zh) 2019-01-07 2020-01-06 包含經修飾il-2多肽之多肽及其用途

Country Status (15)

Country Link
US (1) US20220089667A1 (cg-RX-API-DMAC7.html)
EP (1) EP3908596A1 (cg-RX-API-DMAC7.html)
JP (2) JP7594161B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210113265A (cg-RX-API-DMAC7.html)
CN (1) CN113924311A (cg-RX-API-DMAC7.html)
AR (1) AR117770A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020206672B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012294A2 (cg-RX-API-DMAC7.html)
CA (1) CA3125529A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001779A1 (cg-RX-API-DMAC7.html)
IL (1) IL284633A (cg-RX-API-DMAC7.html)
MX (1) MX428580B (cg-RX-API-DMAC7.html)
SG (1) SG11202106700WA (cg-RX-API-DMAC7.html)
TW (1) TWI874345B (cg-RX-API-DMAC7.html)
WO (1) WO2020146221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CA3148135A1 (en) 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
WO2021050554A1 (en) 2019-09-10 2021-03-18 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
CN115916831A (zh) * 2020-06-30 2023-04-04 Gi 医诺微新 包含抗lag-3抗体和il-2的融合蛋白及其用途
EP4175979A2 (en) * 2020-07-02 2023-05-10 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
JP2023553216A (ja) * 2020-12-09 2023-12-20 アシャ バイオセラピューティクス,インク. 遺伝子操作細胞療法のための標的化サイトカイン構築物
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
CA3213751A1 (en) * 2021-03-31 2022-10-06 Ziyang Zhong Fusion proteins, pharmaceutical compositions, and therapeutic applications
TW202321283A (zh) * 2021-07-20 2023-06-01 美商英伊布里克斯公司 Cd8結合多肽及其用途
TW202309102A (zh) * 2021-07-20 2023-03-01 美商英伊布里克斯公司 靶向cd8之經修飾il-2多肽及其用途
TW202319397A (zh) * 2021-08-30 2023-05-16 美商英伊布里克斯公司 NKp46結合多肽及其用途
TW202328171A (zh) * 2021-08-30 2023-07-16 美商英伊布里克斯公司 靶向NKp46之經修飾之IL-2多肽及其用途
JP2024536840A (ja) * 2021-09-26 2024-10-08 ウーシー バイオロジクス アイルランド リミテッド Il-2バリアント及びその融合タンパク質
TW202334193A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 靶向γδ T細胞之經修飾IL-2多肽及其用途
WO2024026449A2 (en) * 2022-07-28 2024-02-01 Proviva Therapeutics (Hong Kong) Limited Il-2 procytokine antibody fusion proteins
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086798A2 (en) * 2004-03-05 2005-09-22 Chiron Corporation Improved interleukin-2 muteins
US7186804B2 (en) * 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
TW201718029A (zh) * 2011-02-10 2017-06-01 羅齊克雷雅公司 突變介白素-2多肽
CN108884157A (zh) * 2016-01-11 2018-11-23 苏黎世大学 包含针对白介素2的超级激动剂抗体和检查点阻断剂的组合疗法
WO2018234862A1 (en) * 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN102101885B (zh) 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
WO2013180200A1 (ja) * 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
KR20240005989A (ko) * 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
CA3052532A1 (en) * 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186804B2 (en) * 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
WO2005086798A2 (en) * 2004-03-05 2005-09-22 Chiron Corporation Improved interleukin-2 muteins
TW201718029A (zh) * 2011-02-10 2017-06-01 羅齊克雷雅公司 突變介白素-2多肽
CN108884157A (zh) * 2016-01-11 2018-11-23 苏黎世大学 包含针对白介素2的超级激动剂抗体和检查点阻断剂的组合疗法
WO2018234862A1 (en) * 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof

Also Published As

Publication number Publication date
WO2020146221A1 (en) 2020-07-16
MX428580B (es) 2025-11-13
KR20210113265A (ko) 2021-09-15
JP7594161B2 (ja) 2024-12-04
AU2020206672B2 (en) 2025-10-02
CN113924311A (zh) 2022-01-11
JP2025013911A (ja) 2025-01-28
CA3125529A1 (en) 2020-07-16
MX2021008147A (es) 2021-08-11
TW202043259A (zh) 2020-12-01
JP2022516557A (ja) 2022-02-28
BR112021012294A2 (pt) 2021-09-08
IL284633A (en) 2021-08-31
AU2020206672A1 (en) 2021-07-15
SG11202106700WA (en) 2021-07-29
AR117770A1 (es) 2021-08-25
AU2025283608A1 (en) 2026-01-22
CL2021001779A1 (es) 2022-03-04
EP3908596A1 (en) 2021-11-17
US20220089667A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
JP7594161B2 (ja) 修飾il-2ポリペプチドを含むポリペプチド及びその使用
US12012459B2 (en) OX40-binding polypeptides and uses thereof
US20230235005A1 (en) Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
TW202321283A (zh) Cd8結合多肽及其用途
TW202319397A (zh) NKp46結合多肽及其用途
TW202328171A (zh) 靶向NKp46之經修飾之IL-2多肽及其用途
TW202309102A (zh) 靶向cd8之經修飾il-2多肽及其用途
US20220267420A1 (en) Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
RU2849624C2 (ru) Полипептиды, содержащие модифицированный полипептид il-2, и их применения
RU2802070C2 (ru) Ох40-связывающие полипептиды и их применение